Abstract: Solid dispersions of poorly soluble drugs are disclosed which are prepared using a solvent or fusion process. Such dispersions are manufactured with the free base of the drug, specifically paroxetine free base, an oil, allowing for a low temperature for the fusion process, decreased organic solvent volumes for the solvent process and the formation of a paroxetine salt during the solid dispersion manufacture process.

Abstract: The present invention relates generally to a method for, and pharmaceutical compositions useful in, the prophylaxis and/or treatment of cardiac dysfunction in a mammal by the administration of an effective amount of an agent capable of blocking or inhibiting the effect or release of inositol(1,4,5)trisphosphate in cardiac tissue.

Abstract: Novel cryptolepine analogs useful as hypoglycemic agents and methods for their use as hypoglycemic agents, for example, in the treatment of diabetes, and a method for their synthesis are described. As hypoglycemic agents, the novel cryptolepine analogs are useful for the treatment of insulin-dependent diabetes mellitus (IDDM or Type I) and non-insulin dependent diabetes mellitus (NIDDM or Type II).

Abstract: The pharmaceutical composition, especially for treating skin with seborrhea, Acne vulgaris and androgonically conditioned alopecia, contains a hormonal agent including the gestogen, dienogest, or a combination of dienogest and an estrogen, as active ingredient. Methods for treatment of this type of skin condition include topical application of the composition including the dienogest which results in an outstanding sebosuppression, a drastic reduction of androstandiol glucuronide and a moderate competitive blockage of androgen receptor sites. Galenic formulations are described which limit and/or prevent the permeation of the active ingredient through the skin.

Abstract: The invention relates to methods and compositions for delivering iron to an iron-deficient patient, more particularly, to methods whereby an iron complex comprising divalent or trivalent ionic iron complexed with one or more low molecular weight anions is administered to a patient by transfer from dialysate. A complex selected according to the invention is non-polymeric; soluble in an aqueous medium; chemically stable, thereby preventing the dissociation of iron ions from the anions under conditions according to the invention; and can be well absorbed into blood and the living body. Also provided are dialysate compositions including therein an iron complex selected according to the invention, and dialysate concentrates which may be diluted to yield an inventive dialysate composition.

Abstract: A pharmaceutical composition for trans-mucosal or transdermal administration wherein a per-C.sub.2-18 acylated cyclodextrin is used as a drug reservoir or carrier. The composition can be used safely and exhibits excellent drug release behavior.

Abstract: Substituted indenyl sulfonyl acetic acids, esters and alcohols are useful in the treatment of psoriasis.

Abstract: An edible composition comprising a mixture of at least two herbs selected from the group consisting of Syzygium cumini, Gymnema sylvestre, Momordica charantia and Solanum melongena. Preferably, the composition comprises a mixture of Syzygium cumini and Momordica charantia. A mixture of Syzygium cumini, Gymnema sylvestre and Momordica charantia is particularly preferred. The herbal mixtures are useful as dietary supplements and are especially useful for lowering the glucose level of the blood in mammals, particularly humans suffering from diabetes mellitus.

Abstract: The present invention relates to the administration of an effective amount of turmeric for the treatment of various health ailments and also as a food supplement to promote health and vitality. The turmeric is especially useful for the treatment of skin disorders, such as acne, when administered orally. It can also be used to treat liver and stomach disorders, skin discoloration, constipation, and hemorrhoids.

Abstract: The present invention is based in part upon the discovery that the use of pyruvate in enteral formulations, in combination with an anabolic protein composition, produces a synergistic effect in increasing the lean body mass or muscle tissue of a mammal consuming same. The present invention also provides a method for enhanced endurance of athletes.The present invention relates generally to a composition for enhancing the protein concentration or muscle mass of a mammal and a method for enhancing the protein concentration or muscle mass in a mammal. More specifically, the present invention relates to a composition which comprises pyruvate and/or derivatives of pyruvate and an anabolic protein composition. The method of the present invention comprises administering to a mammal in need of enhancing its protein concentration or muscle mass, a composition comprising pyruvate and an anabolic protein composition.

Abstract: Topical formulations having a content of one compound or several compounds from the group consisting of ubiquinones and derivatives thereof in combination with a content of one compound or several compounds from the group consisting of plastoquinones and derivatives thereof or formulations having a content of one compound or several compounds from the group consisting of plastoquinones and derivatives thereof.

Abstract: A stable solid dispersion of prostaglandin drug, particularly Misoprostol, (.+-.)methyl 7-?3(.alpha.)-hydroxy-2-.beta.-(4 (RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-oxycyclopent-1.alpha.-yl!hepta noate, comprising ammonio methacrylate copolymers. The ammonio methacrylate copolymers comprise Eudragit RS series, Eudragit RL series, Eudragit S, Eudragit L, and the mixture thereof. The stable solid dispersion is a sustained release type.

Abstract: A pharmaceutical composition for use in the treatment of psoriasis, having isopropyl myristate as its only active ingredient.

Abstract: A composition to be applied in the preservation of edible sea products exposed to melanization is disclosed; said composition being composed of potassium or sodium bisulfite, organic acids acceptable from the alimentary point of view, such as citric acid or tartaric acid and acid salts of the same, ascorbic acid or its salts and L-cysteine or N-acetyl-cysteine as an enzymatic inhibitor, antioxidant, sequestrate.

Abstract: A dietary supplement for canines and felines includes taurine in a liquid lecithin base. The dietary supplement has proven effective in reducing epileptic seizures in canines and in reducing behavioral problems, such as aggression, in canines. In addition, the dietary supplement is more easily digestible than conventional tablet forms of taurine and is more effectively administered to felines for treatment of cardiomyopathy.

Abstract: A skin tightening aqueous gel formed from the combination of water, a dispersed finely particulate vegetable based tautening or tensor agent, a polymeric gelling agent, a liquid hydrocarbon dispersing aid and a nonionic surfactant.There is described a method of dispensing and spreading the gel onto skin areas for the tightening treatment.

Abstract: The method of this invention is directed to a treatment of depression in men and women and to a treatment of pre-menstrual syndrome (PMS) in women by administering to a patient a therapeutically effective amount of chromium in a pharmaceutically acceptable form either alone or in conjunction with the administration of a standard antidepressant composition, such as a selective serotonin reuptake inhibitor composition. Chromium, preferably in the form of chromium picolinate, is administered to the patient at dosages in a preferred range of about 200 to about 500 micrograms chromium.

Abstract: Compositions comprising a mixture of 2-(thiocyanomethylthio)benzothiazole and methylene-bis(thiocyanate) with dimethylamide of a carboxylic acid are disclosed which are synergistically effective compared to the respective components alone in controlling the growth of microorganisms in or on a product, material, or medium. Methods to control the growth of microorganisms and prevent spoilage caused by microorganisms with the use of the compositions of the present invention are also disclosed.

Abstract: A pre-mix insecticidal composition is disclosed that contains (a) 0.1-10% by weight of 2,4-dioxo-1-(2-propynyl)imidazolidin-3-ylmethyl chrysanthemate, (b) 2.5-50% by weight of a fatty acid ester of 16-19 carbon atoms; (c) 2.5-30% by weight of a sorbitan fatty acid ester; (d) 0.5-1% by weight of at least one alcohol selected from the group consisting of ethanol, 1-propanol, 2-propanol, ethylene glycol, diethylene glycol, triethylene glycol, propylene glycol, dipropylene glycol, butylene glycol and glycerin; and (e) 40-93.5% by weight of a saturated hydrocarbon of 8-18 carbon atoms. This pre-mix insecticidal composition exhibits little, if any, precipitation when left to stand. It is sufficiently stable to be transported and is storage stable prior to formulating an insecticidal aerosol composition. A useful insecticidal aerosol composition contains 5-30% by weight of this pre-mix insecticidal composition, 40-85% by weight of water and 10-50% by weight of a propellant. The aerosol composition is stable, i.e.

Abstract: Relief from the symptoms of rhinitis is obtained by treatment with: (a) an antihistaminic effective amount of a histamine H.sub.1 receptor antagonist; together with (b) a sufficient amount of a histamine H.sub.3 receptor antagonist to provide a nasal decongestant effect. The components may be administered together in a single dosage form, or separately in the same or different dosage forms to maintain therapeutic systemic levels of both components.